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orders and osteoporosis is increasing in Asia. Objectives: To conduct
a systematic review of the published literature to identify studies
examining disorders of glucose and lipid metabolism (type 2 diabetes,
hyperglycemia, hypercholesterolemia, hyperlipidemia, dyslipidemia,
metabolic syndrome [MetS], and atherosclerosis) as risk factors for
osteoporosis and fracture in Asian populations. Studies examining
the relationship between metabolic disorders and bone mineral
density (BMD) were also included.Methods: EMBASE (including MED-
LINE) and the Cochrane Library were searched. Studies conducted
only within Asia, which reported multivariate analysis with a sample
size of 200 or more subjects, were included. Results: A total of 32
studies were included. All six studies examining diabetes and fracture
found that subjects with diabetes had a signiﬁcantly higher risk of
fracture than did subjects without diabetes (risk estimate range
1.26–4.73). Two studies found that subjects with atherosclerosis had
a signiﬁcantly higher risk of fracture (risk estimate range 1.10–2.52).ee front matter Copyright & 2016, International S
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st: The authors have indicated that they have no
sayo@lilly.com.
ndence to: Masayo Sato, 7-1-5 Isogamidori, Chuo-kStudies consistently reported that MetS is likely associated with
osteoporosis or decreased BMD in men but not women. No consistent
association was found for diabetes and BMD, with studies reporting
contrasting results. There was limited evidence investigating lipid
metabolism and hyperglycemia and risk of fracture or bone loss in
Asian populations. Conclusions: These ﬁndings suggest that diabetes
is a risk factor for fracture in Asian populations. MetS may be
associated with bone loss in Asian men and atherosclerosis associ-
ated with increased fractures; however, caution is needed interpret-
ing these ﬁndings given limitations in study design.
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syndrome, osteoporosis, type 2 diabetes.
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Osteoporosis is a skeletal disorder characterized by decreased
bone mass and deterioration of bone microarchitecture, leading
to increased bone fragility and susceptibility to fracture. Osteo-
porosis affects more than 200 million people worldwide [1]. The
International Osteoporosis Foundation projects that by 2050 more
than 50% of all osteoporotic fractures will occur in East and
Southeast Asia [2]. Osteoporosis-related fractures have a major
impact on patients’ quality of life and health care costs [2].
Lifestyle-related metabolic disorders include disorders of
glucose metabolism (e.g., diabetes and hyperglycemia) and lipid
metabolism (e.g., hypercholesterolemia and dyslipidemia). Meta-
bolic syndrome (MetS) consists of a combination of impaired
glucose metabolism, dyslipidemia, elevated blood pressure, and
obesity. These metabolic disorders are all important risk factors
for the development of atherosclerosis [3], which is caused by the
slow, progressive accumulation of lipid plaques in arterial walls.The International Diabetes Federation estimates that more
than 200 million people in East and South-East Asia have
diabetes [4]. Furthermore, the prevalence of MetS in Asia is
increasing to similar levels seen in Western countries [5,6].
Increased dietary consumption of fat and sugar, as well as
decreased physical activity and above normal weight gain, has
contributed to an increase in the prevalence of lifestyle-related
metabolic disorders in Asia. In addition, healthy East and South-
East Asians have been shown to have a higher percentage of body
fat than do Caucasians at a given body mass index (BMI). Lower
insulin sensitivity has also been reported in South Asian pop-
ulations, suggesting greater genetic susceptibility to developing
lifestyle-related metabolic disorders [6,7]. Research has also
shown that Japanese subjects are at an increased risk of type 2
diabetes due to lower insulin secretion capacity [8,9].
The recent Japan Osteoporosis Society handbook has high-
lighted lifestyle-related metabolic disorders as potential risk
factors for osteoporosis and fracture [10]. Research shows thatociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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signaling regulates the differentiation of osteoblast cells and
bone resorption by osteoclasts [11,12]. Furthermore, increased
insulin resistance and body fat is associated with decreased
osteocalcin levels [13]. Thus, it is hypothesized that imbalances
in glucose/fat metabolism may affect bone quality, leading to the
development of osteoporosis.
A systematic review of epidemiological studies found diabetes
to be a risk factor for fracture in the United States and Europe [14].
At the time of the review (2006), there were no studies included in
the review from Asia. In contrast, a meta-analysis examining the
association of MetS and fracture suggested that MetS may have a
small protective effect [15]. The authors noted caution in inter-
preting this ﬁnding, with a high degree of heterogeneity and wide
conﬁdence intervals (CIs) observed.
Meta-analyses examining the relationship between metabolic
disorders and bone loss have produced differing results. Two
meta-analyses showed that subjects with diabetes had higher
bone mineral density (BMD) compared with subjects without
diabetes [16,17]. Another meta-analysis found that subjects with
and without MetS had similar BMD [15], whereas another review
concluded that MetS is associated with increased risk for osteo-
porosis in men but not women [18]. A high degree of hetero-
geneity, both in the populations included and results found, was
observed between studies included in the meta-analyses.
Given the rapidly increasing rate of lifestyle-related metabolic
disorders, the aim of this systematic review was to summarize all
published studies on the association between disorders of glu-
cose and lipid metabolism (speciﬁcally type 2 diabetes, hyper-
glycemia, lipid metabolism, MetS, and atherosclerosis) and risk of
fracture and osteoporosis in Asian populations. The relationship
between metabolic disorders and BMD was also examined.Methods
Literature Search Strategy
A systematic review of the published literature was conducted to
identify studies examining metabolic disorders as risk factors for
osteoporosis and fracture as well as studies examining the
relationship between metabolic disorders and BMD. The data-
bases searched were EMBASE.com (includes MEDLINE and
EMBASE) (January 1, 1990, to October 8, 2013), and the Cochrane
Library (to October 8, 2013). The overall search strategy included
terms for osteoporosis, BMD, fracture, diabetes, metabolic syn-
drome, atherosclerosis, hyperglycemia, hypercholesterolemia,
hyperlipidemia, and dyslipidemia. The search was not limited
by country or language. In addition, a manual search of the
references of relevant systematic reviews and included studies
was conducted. The literature search strategies for EMBASE.com
and Cochrane databases are included in Appendix Table 3 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.vhri.
2015.09.005.
Selection Criteria
Studies reporting the following risk factors were included: Type 2 diabetes
 Hyperglycemia
 Hypercholesterolemia, hyperlipidemia, and dyslipidemia
 MetS
 AtherosclerosisOnly those studies that reported the deﬁnition of risk factors
used were included. Studies speciﬁcally in type 1 diabetes wereexcluded. Studies that did not distinguish between type 1 and
type 2 diabetes were included.
Only studies conducted within Asia (including East, South-
east, and South Asia and the Middle East), which reported
multivariate analysis in a sample size of 200 or more subjects,
were included. A sample size cutoff of 200 was chosen to allow
for dropout, confounding, and missing data for covariates. For
fractures, studies reported risk estimates (odds ratio, hazard
ratio, or relative risk) and corresponding CIs. For BMD, studies
reported risk estimates for osteoporosis (i.e., BMD T score o–2.5)
or osteopenia (i.e., BMD T score o–1 and 4–2.5). In addition,
studies reporting mean values of BMD and variance (standard
errors, SDs, or 95% CIs) in patients with and without metabolic
disorders were included. When studies reported multiple sites,
BMD of lumbar spine (LSBMD), femoral neck (FNBMD), and total
hip (THBMD) were included in the review.Data Extraction and Quality Assessment
Data were extracted independently by two reviewers (F.D. and B.
A.). The following data were retrieved from each article: ﬁrst
author, year of publication, year of patient recruitment, country
where study was conducted, study design, length of follow-up (if
applicable), participant inclusion/exclusion criteria, method of
risk factor disease diagnosis, sample size, age, sex, controlled
variables, adjusted fracture and osteoporosis risk estimates with
corresponding 95% CIs, adjusted mean BMD, and corresponding
standard errors, SDs, or 95% CIs.
Study quality was assessed using checklists for cohort and
case-control studies developed by the Scottish Intercollegiate
Guidelines Network [19]. Studies were assessed asþþ(high quality:
most of the criteria met; little or no risk of bias. Results unlikely
to be changed by further research), þ (acceptable: most criteria
met. Some ﬂaws in the study with an associated risk of bias.
Conclusions may change in the light of further studies) or 0 (low
quality: either most criteria not met, or signiﬁcant ﬂaws relating
to key aspects of study design. Conclusions likely to change in the
light of further studies).Results
A total of 6168 publications were identiﬁed from the literature
search, including 5967 from EMBASE.com, 195 from Cochrane
database, and 6 from a hand search of references from relevant
studies. Following the review of titles and abstracts, 6115 were
excluded and the remaining 53 articles were sourced for full-text
review. After reviewing the full text, 21 articles were excluded
(Fig. 1). Ultimately, the literature search identiﬁed 32 studies for
inclusion [20–51].
The characteristics of included studies are summarized in
Table 1. There were 28 studies conducted in East and Southeast
Asia (9 studies in South Korea, 6 studies in Japan, 3 studies in
mainland China, 3 studies in Hong Kong, 5 studies in Taiwan, 1
each in the Philippines and Singapore) and 4 in the Middle East (2
studies in Jordan, 1 each in Turkey and Israel). Most of the studies
were cross-sectional study design (24 studies), with four retro-
spective cohort, two prospective cohort, and two case–control.
Diabetes was the most commonly reported metabolic disorder
(16 studies including 6 speciﬁcally in type 2 diabetes), followed by
MetS (10 studies), atherosclerosis (5 studies), lipid disorders (3
studies), and hyperglycemia (1 study). There were 10 studies
examining the risk of fracture, 8 studies examining the risk of
osteoporosis (deﬁned as BMD T score o–2.5 in 5 studies), and 14
studies reporting differences in BMD between patients with and
without metabolic disorders.
Fig. 1 – Flow diagram of study selection.
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was the highest quality score that could be assigned to studies
with a cross-sectional or retrospective design. One prospective
cohort study was rated as high quality (þþ) (Table 1). All studies
met at least 70% of applicable criteria. Importantly, all studies
reported well-deﬁned outcomes and appropriately adjusted for
confounders via multivariate analyses.
The studies varied in patient inclusion/exclusion criteria (see
Appendix Table 4 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.vhri.2015.09.005). There were 13 studies that
included both men and women, 2 studies in men only and 17
studies in women only. Of the studies in women, 14 studies
speciﬁed postmenopausal. In general, larger, population-based
studies had less restrictive exclusion criteria compared with
smaller studies. Common exclusion criteria were patients taking
osteoporosis medication (17 studies), hormone medication (13
studies), or with other disorders known to affect bone metabo-
lism (9 studies).
Studies reporting risk estimates (relative risk [RR], odds ratio
[OR], hazard ratio) for fracture or osteoporosis are summarized in
Figs. 2 and 3. Further details of these studies are presented in
Appendix Table 5 in Supplemental Material found at http://dx.
doi.org/10.1016/j.vhri.2015.09.005. In addition, there were three
studies reporting mean difference in BMD between patients with
and without metabolic disorders [24,37,38] (see Appendix
Table 5). Appendix Table 2 summarizes cross-sectional studies
reporting mean BMD for patients with and without metabolic
disorders. For most of the studies, the metabolic risk factor was
the predictor, with fracture, osteoporosis, or BMD as the outcome.
In addition, two studies [22,23] presented osteoporosis as the
predictor and atherosclerosis as the outcome.
Studies varied in the potential confounders, which were
adjusted for in the analyses (see Appendix Table 5). The most
commonly controlled variables were age (29 studies), BMI or
weight (22 studies), and smoking (18 studies).Atherosclerosis
Two studies reported the risk of fractures associated with
atherosclerosis [20,21] (Fig. 2). Both studies found that subjects
with atherosclerosis had a signiﬁcantly higher risk of fracture
than did subjects without atherosclerosis (risk estimate range
1.10– 2.52).Two studies examined the relationship between atheroscle-
rosis and bone loss [22,23]. Choi et al. [22] reported that women
but not men with a BMD T score of less than –1.5 (i.e., including
subjects with osteoporosis or osteopenia) had a signiﬁcantly
higher risk of atherosclerosis (OR 5.84; 95% CI 1.09–31.20)
(Fig. 3). Tamaki et al. [23] reported that women with osteoporosis
(BMD T score o–2.5) had higher intima-media thickness of
carotid bifurcation (a measure of atherosclerosis development)
(Appendix Table 2).
Two studies reported BMD in subjects with and without
atherosclerosis [22,24]. Wong et al. [24] reported that subjects
with atherosclerosis had signiﬁcantly lower THBMD than did
subjects without atherosclerosis (see Appendix Table 5). This
was not signiﬁcant for LSBMD. Choi et al. [22] did not report
a signiﬁcant association between BMD and atherosclerosis
(Appendix Table 2).
Diabetes
All studies examining diabetes and fracture found that subjects
with diabetes had a signiﬁcantly higher risk of fracture than did
subjects without diabetes (risk estimate range: 1.26–4.73) [25–30]
(Fig. 2). This included the high-quality, prospective cohort study
by Koh et al. [28], which found that men and women with
diabetes were at a signiﬁcantly higher risk of hip fracture (RR
1.98; 95% CI 1.71–2.29).
Six studies examined diabetes as a risk factor for osteoporosis
(as deﬁned by BMD) [31–36] (Fig. 3). Of these, two studies in
women [31,32] and one study in men and women [33] reported
that patients with diabetes had a higher risk of osteoporosis. In
contrast, two studies in women reported a lower risk [34,35].
Shan et al. [35] reported a signiﬁcantly lower risk when osteopo-
rosis was assessed at the spine (OR 0.68; 95% CI 0.56–0.83) but not
at femoral neck or total hip. One study reported no signiﬁcant
association between osteoporosis and type 2 diabetes; however,
wide CIs were reported [36].
Four studies reported BMD in subjects with and without
diabetes [37–40] (see Appendix Tables 2 and 5 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.vhri.2015.09.005).
Two studies found that men and women with diabetes had
signiﬁcantly higher BMD than did subjects without diabetes
[37,38]. One study reported signiﬁcantly lower BMD [39], and
one study reported no signiﬁcant difference [40]. Notably, neither
study controlled for age, BMI, or weight in the analysis.
Metabolic Syndrome
In one study reporting fractures, MetS was not associated with
fracture risk [41] (Fig. 2). Kim et al. [42] found that men but not
women with MetS had a signiﬁcantly increased risk of osteopenia
or osteoporosis (OR 1.49; 95% CI 1.04–2.14) (Fig. 3).
Eight studies reported BMD in subjects with and without MetS
[43–50] (Appendix Table 2). Two studies reported that men with
MetS have signiﬁcantly lower FNBMD or THBMD than did men
without MetS [43,44], whereas one study observed no signiﬁcant
difference in men [45].
Three studies reported signiﬁcantly lower LSBMD or FNBMD in
women with MetS compared with subjects without MetS
[43,46,47]. Four studies reported no signiﬁcant difference at
LSBMD, FNBMD, or foot BMD [44,45,48,49]. One longitudinal study
reported that women with MetS have signiﬁcantly less reduction
in LSBMD and FNBMD than do women without MetS [50].
Lipids
Two studies reported the risk of fractures associated with lipid
levels [30,51] (Fig. 2). No association was found between fracture
and hypercholesterolemia [51] or dyslipidemia [30]. Women with
Table 1 – Study characteristics.
Publication ID Country Study type Time period
(year)
Metabolic disorder Diagnosis deﬁnition Outcome Length of
follow-up
Quality
assessment
of study
Lai et al. [20] Taiwan Retrospective cohort 2000– 2007
(baseline)
Atherosclerosis ICD-9 440–448 Fracture 6 y þ
Wada et al. [21] Japan Cross- sectional 2008– 2009 Atherosclerosis Breast arterial calciﬁcation Fracture NA þ
Choi et al. [22] Korea Cross- sectional 2005–2008 Atherosclerosis Aortic valve sclerosis Osteoporosis NA þ
Tamaki et al. [23] Japan Prospective cohort 1996–2006 Atherosclerosis Intima-media thickness of
carotid bifurcation
BMD 10 y þ
Wong et al. [24] Hong Kong Cross- sectional 2001– 2004 Atherosclerosis Peripheral vascular disease as
ankle brachial index o0.90
BMD NA þ
Chen et al. [25] Taiwan Retrospective cohort 1997–2002 Diabetes ICD-9 250 or A code 181 Fracture NA þ
Segal et al. [26] Israel Case-control NR Diabetes Medical examination Fracture NA þ
Yamamoto et al. [27] Japan Cross- sectional NR Diabetes type 2 Referred to clinic for treatment
of diabetes
Fracture NA þ
Koh et al. [28] Singapore Prospective cohort 1993–1998
(baseline)
Diabetes Physician-diagnosed diabetes Fracture 12.2 y þþ
Soong et al. [29] Taiwan Retrospective cohort 2004–2005
(baseline)
Diabetes NR Fracture 1 y þ
Tatsuno et al. [30] Japan Cross- sectional 2001–2009 Diabetes
Dyslipidemia
Medical history Fracture NA þ
Li et al. [31] China Cross- sectional 1998–2008 Diabetes Medical history of diabetes Osteoporosis NA þ
El-Heis et al. [32] Jordan Cross- sectional 2009–2010 Diabetes Medical history of diabetes Osteoporosis NA þ
Shaw 1993 [33] Taiwan Cross- sectional 1988–1989 Diabetes Medical history of diabetes Osteoporosis NA þ
Romana and Li-Yu [34] Philippines Case-control 2000–2003 Diabetes type 2 Medical history of diabetes Osteoporosis NA þ
Shan et al. [35] China Cross- sectional 1997–2005 Diabetes type 2 American Diabetes
Association
Osteoporosis NA þ
Shilbayeh 2003 [36] Jordan Cross- sectional 2000–2002 Diabetes type 2 Medical history of diabetes Osteoporosis NA þ
Khoo et al. (Ms OS) [37] Hong Kong Cross- sectional 2002–2003 Diabetes Patient questionnaire BMD NA þ
Lau et al. (Mr OS) [38] Hong Kong Cross- sectional NR Diabetes Patient questionnaire BMD NA þ
Chen et al. [39] China Cross- sectional 2007–2008 Diabetes type 2 WHO criteria BMD NA þ
Anaforoglu et al. [40] Turkey Cross- sectional 2005–2006 Diabetes type 2 Physician-diagnosed diabetes BMD NA þ
Kim et al. [41] Korea Cross- sectional NR MetS NCEP-ATP III criteria Fracture NA þ
Kim et al. [42] Korea Cross- sectional 2005 MetS AHA/NHLBI criteria Osteoporosis NA þ
Kim et al. [43] Korea Cross- sectional 2005–2006 MetS AHA/NHLBI criteria BMD NA þ
Kim et al. [44] Korea Cross- sectional 2008–2010 MetS AHA/NHLBI criteria BMD NA þ
Tseng et al. [45] Taiwan Cross- sectional 2007 MetS NCEP-ATP III criteria BMD NA þ
Hwang and Choi [46] Korea Cross- sectional 2006–2007 MetS
Hypertriglyceridemia
Hyperglycemia
NCEP-ATP III criteria BMD NA þ
Jeon et al. [47] Korea Cross- sectional 2006–2009 MetS AHA/NHLBI criteria BMD NA þ
Park et al.[48] Korea Cross- sectional 2004–2008 MetS NCEP-ATP III criteria BMD NA þ
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V A L U E I N H E A L T H R E G I O N A L I S S U E S 9 C ( 2 0 1 6 ) 4 9 – 5 6 53high triglycerides had a signiﬁcantly lower risk of fractures (OR
0.51; 95% CI 0.29–0.89) [51]. In contrast, women with high
triglycerides had lower LSBMD [46].
Hyperglycemia
There was no signiﬁcant difference in BMD between subjects with
and without hyperglycemia [46] (Appendix Table 2).Discussion
Evidence presented in this review suggests that diabetes is a risk
factor for fracture in Asian men and women. The association
between diabetes and fracture was observed in both men and
women and for all fracture sites presented in the included
studies. In particular, three studies found an association between
diabetes and increased hip fracture risk. This association was
also consistent for studies carried out in different regions within
Asia. Importantly, this included high-quality evidence from pro-
spective cohort studies suggesting a strong association between
diabetes and fracture. This conﬁrms the ﬁndings of a previous
systematic review that found that diabetes was strongly associ-
ated with increased risk of hip fracture in US and European
populations [14].
In contrast, the present review did not ﬁnd a consistent
association between diabetes and BMD in Asian populations.
There was a high degree of heterogeneity between studies, which
reported contrasting results. This ﬁnding differs somewhat from
a previous meta-analysis in predominantly US and European
populations, which demonstrated that patients with diabetes
have a higher BMD [17]. Another recent meta-analysis reported
a similar ﬁnding [16], although a high degree of heterogeneity
was also noted, for which Asian ethnicity was a signiﬁcant
source. The reasons for greater heterogeneity in Asian popula-
tions are unclear. Notably, studies reporting this association in
the present review were from diverse regions across Asia. As
such, there may be cultural or lifestyle differences that account
for the differences in ﬁndings. For example, studies have con-
sistently shown that higher socioeconomic development is asso-
ciated with increased risk of fractures [52]. Dietary calcium and
vitamin D levels also differ between regions, with very high levels
of vitamin D deﬁciency in postmenopausal women in Japan and
Korea [53]. Genetic differences may also be important. The risk of
fracture has heritable elements that are independent of BMD
such as differences in bone geometry, size, and height [52,54].
Further prospective, longitudinal studies are needed to explore
the interaction between diabetes and other potential risk factors
on BMD and fracture in Asian populations. That diabetes may
increase fracture risk without negatively affecting BMD appears
to be counterintuitive. It has been suggested, however, that
diabetes affects aspects of bone quality other than BMD, or other
factors that are completely independent of bone metabolism. For
example, diabetes may accelerate the formation of advanced
glycation end products in bone, which causes oxidative stress
and affects bone collagen quality [55–57]. Diabetic patients may
also have an increased risk of falls due to diabetic retinopathy or
peripheral neuropathy [58,59].
The present review suggests that Asian men with MetS may
be at a higher risk of bone loss, a ﬁnding supported by a recent
meta-analysis [18]. In addition, a lower BMD was reported in men
with MetS than in men without MetS in two studies [43,44] with
no signiﬁcant difference reported in a third study [45]. Again, this
ﬁnding should be interpreted with caution because studies
examining this relationship were of cross-sectional design. In
contrast, the relationship between MetS and bone loss in Asian
women is unclear, with studies showing contrasting results. The
0.100 1.000 10.000
Lai 2013 [20]: A (87,748)
 M (46,322)
 W (41,426)
Wada 2012 [21]: PMW (421)
Chen 2008 [25]:  M (454,592)
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Segal 2009 [26]: All (238)
 W (198)
Yamamoto 2009 [27]: PM W (759)
 M (237)
Koh 2010 [28]: All (63,154)
 M (27,939)
 W (35,215)
Soong 2013 [29]: All (32,604)
Tatsuno 2013 [30]: PMW (64,809)
Kim 2010b [41]: PMW (900)
Yamaguchi 2002 [51]:
PMW (214): T-C
 LDL-C
 HDL-C
 TG
Tatsuno 2013 [30]: PMW: Dys
Risk esmate* (95% CI)
Protecve                                         Risk
Atherosclerosis
Diabetes
MetS
Lipids
Fig. 2 – Association between metabolic disorders and fracture. A, all patients; Dys, dyslipedemia; HDL-C, high-density
lipoprotien cholesterol; LDL-C, low-density lipoprotein; M, men; MetS, metabolic syndrome; PMW, postmenopausal women;
T-C, total cholesterol; TG, triglyceride; W, women. *Studies presented odds ratio, relative risk, or hazard ratio.
Logarithmic scale.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 9 C ( 2 0 1 6 ) 4 9 – 5 654reasons for the impact of sex are yet to be elucidated. Most of the
women included in these studies were postmenopausal. Meno-
pause is one of the main risk factors for osteoporosis in part
because of decreased estrogen production. It has been postulated
that increased adipose tissue associated with MetS is a main
source of estrogen in postmenopausal women, which may have a
protective effect on bone [60]. In contrast, it has been hypothe-
sized that higher visceral fat may cause greater hormone imbal-
ances in men than in women, which negatively affects bone
formation [44]. The effect of higher visceral fat may be partic-
ularly enhanced in Asian men because a higher percentage of
body fat has been observed in East and South-East Asians than in
Caucasians at a given BMI [6,7].
Studies presented in this review found that atherosclerosis
may also be associated with increased fracture risk. This ﬁnding,
however, should be treated with caution because it is based on
one cross-sectional and one retrospective study. There was also
high heterogeneity in the diagnosis deﬁnition of atherosclerosis.
Chronically high circulating lipids (which are a primary cause of
atherosclerosis) have been hypothesized to increase the risk of
osteoporosis. Adipose tissue affects the differentiation of osteo-
blasts, with increased adipose tissue in bone marrow associated
with osteoporosis [61]. Increased oxidative stress through lipid
oxidation, as well as pro-inﬂammatory adipokines, may also
inhibit osteoblast differentiation while enhancing osteoclast
differentiation [62]. Furthermore, both statins and bisphospho-
nates inhibit the 3-hydroxy-3-methylglutaryl-coenzyme A reduc-
tase pathway (also known as the mevalonate pathway), which
regulates cholesterol production as well as contributes to osteo-
clast regulation [63].In contrast, one study identiﬁed in the present review sug-
gests that triglycerides may have a protective effect for fracture
[51]. Although not a focus of the present review, high abdominal
fat may be associated with decreased risk of fractures in women
and subjects with type 2 diabetes [64,65]. It has been speculated
that high body fat and high triglycerides per se may have a
protective effect, possibly through increased production of estra-
diol [66], increased mechanical load [50], or a cushioning effect
around the skeleton [60].
This review has several limitations. Most of the studies
included in the review were cross-sectional design. Therefore,
with the exception of diabetes (which included longitudinal
cohort studies), the ﬁndings of this review should be treated with
caution. There was also limited evidence exploring the associa-
tion between MetS, hyperglycemia or hypercholesterolemia and
the risk of fractures in Asian populations. This highlights the
need for prospective cohort studies in Asian populations mon-
itoring the development of metabolic disorders, fracture, BMD,
and other measures of bone quality (which are potentially
predictive of fracture).
Meta-analyses were not undertaken as part of this review
because of the high degree of heterogeneity in study design and
patient populations. There was heterogeneity in the risk factor
diagnosis deﬁnitions. In particular, different measures were
used to deﬁne atherosclerosis, MetS, and high lipid levels. Of
16 studies reporting diabetes, 6 used medical history and 2 relied
on self-reporting. This may result in disease misclassiﬁcation,
especially because diabetes is frequently underdiagnosed [67].
Furthermore, 10 studies did not distinguish between type 1 and
type 2 diabetes. Although this may affect the strength of
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Fig. 3 – Association between metabolic disorders and osteoporosis. A, all patients; FN, femoral neck BMD; LS, lumbar spine
BMD; M, men; MetS, metabolic syndrome; PMW, postmenopausal women; TH, total hip BMD; W, women. *All studies
presented odds ratio. Logarithmic scale. Choi et al. [22] presented osteoporosis/osteopenia as the predictor and
atherosclerosis as the outcome.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 9 C ( 2 0 1 6 ) 4 9 – 5 6 55association, the impact is expected to be minimal because less
than 5% cases of diabetes are type 1 in the Asia-Paciﬁc region [4].
There was also heterogeneity in the outcomes presented (i.e. RR,
OR, hazard ratio), method of analysis, and covariates adjusted
for in each study. Many of the studies examining MetS and BMD
excluded subjects taking osteoporosis medication and disorders
known to affect bone metabolism. This was to remove any
potential confounders; however, as a result, subjects with more
severe disease may be excluded from analysis. Furthermore,
important confounders were not always measured and there-
fore not adjusted for in the analyses (e.g., physical activity,
calcium intake, and all relevant medications). In addition,
although a sample size cutoff of 200 or more was chosen to
allow for dropout, confounding, and missing data for covariates,
some studies did not report the number of patients modeled
with all covariates. This could be a substantially smaller cohort
and thus limit generalizability.Conclusions
In summary, ﬁndings from this review suggest that diabetes is a
risk factor for fracture in Asian populations, which is consistent
with ﬁndings in non-Asian populations [14]. MetS may also be
associated with bone loss in Asian men; however, the extent of
causality in these observations is yet to be determined. Studies
presented in this review suggest that atherosclerosis is associ-
ated with increased fractures; however, this ﬁnding must be
interpreted with caution given the small number of studies and
limitations in study design highlighted above. Further prospec-
tive cohort studies are needed to investigate the extent and
mechanisms of these associations in Asian populations. Never-
theless, these ﬁndings highlight the importance of properly
managing patients with these risk factors to minimize the risk
of fractures. In particular, increased awareness through educa-
tion and policy prioritization could assist in reducing the risk of
fractures in patients with diabetes.Acknowledgments
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